Literature DB >> 7995952

Characterization of surface lymphotoxin forms. Use of specific monoclonal antibodies and soluble receptors.

J L Browning1, I Dougas, A Ngam-ek, P R Bourdon, B N Ehrenfels, K Miatkowski, M Zafari, A M Yampaglia, P Lawton, W Meier.   

Abstract

Lymphotoxin (LT) is a cytokine related to TNF, found in human systems in both secreted and membrane bound forms. The well characterized secreted form is a trimer of a single protein, LT-alpha, whereas the surface form is composed of a complex between two related molecules, LT-alpha and LT-beta. Because there is a distinct receptor for the complex, the membrane form is believed to signal via events different from those elicited by TNF and secreted LT-alpha. By using a battery of anti-LT-alpha and LT-beta mAbs, it is clear that two LT surface forms exist on the surface of PMA-activated II-23 cells, a human T cell hybridoma. Assuming that these surface forms are trimers, a minor form appears early after induction having an apparent stoichiometry of LT-alpha 2/beta 1 and is recognized by one group of anti-LT-alpha mAbs and the p55-TNF receptor. The second and predominant form has an apparent LT-alpha 1/beta 2 composition and is recognized by a second group of pantrophic anti-LT-alpha mAbs and the LT-beta receptor. Neither of the heteromeric forms nor a putative LT-beta homotrimeric form were found to be secreted. The properties of surface LT on the II-23 cell system were similar to those of the surface LT forms on Chinese hamster ovary cells transfected with both LT-alpha and LT-beta genes and a number of lymphoid tumor lines. These experiments point toward the LT-alpha 1/beta 2 complex as the predominant membrane form of LT on the lymphocyte surface, and this complex is the primary ligand for the LT-beta receptor.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7995952

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  37 in total

1.  Manipulation of lymphoid microenvironments in nonhuman primates by an inhibitor of the lymphotoxin pathway.

Authors:  Jennifer L Gommerman; Fabienne Mackay; Elina Donskoy; Werner Meier; Pauline Martin; Jeffrey L Browning
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

2.  B lymphocyte-restricted expression of prion protein does not enable prion replication in prion protein knockout mice.

Authors:  F Montrasio; A Cozzio; E Flechsig; D Rossi; M A Klein; T Rülicke; A J Raeber; C A Vosshenrich; J Proft; A Aguzzi; C Weissmann
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

Review 3.  Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring.

Authors:  Raja K Sivamani; Heidi Goodarzi; Miki Shirakawa Garcia; Siba P Raychaudhuri; Lisa N Wehrli; Yoko Ono; Emanual Maverakis
Journal:  Clin Rev Allergy Immunol       Date:  2013-04       Impact factor: 8.667

4.  ICOS, CD40, and lymphotoxin beta receptors signal sequentially and interdependently to initiate a germinal center reaction.

Authors:  Frances Vu; Umberto Dianzani; Carl F Ware; Tak Mak; Jennifer L Gommerman
Journal:  J Immunol       Date:  2008-02-15       Impact factor: 5.422

5.  Role of lymphotoxin alpha in T-cell responses during an acute viral infection.

Authors:  M Suresh; Gibson Lanier; Mary Katherine Large; Jason K Whitmire; John D Altman; Nancy H Ruddle; Rafi Ahmed
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

6.  Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response.

Authors:  Wendy Béguelin; Matt Teater; Cem Meydan; Kenneth B Hoehn; Jude M Phillip; Alexey A Soshnev; Leandro Venturutti; Martín A Rivas; María T Calvo-Fernández; Johana Gutierrez; Jeannie M Camarillo; Katsuyoshi Takata; Karin Tarte; Neil L Kelleher; Christian Steidl; Christopher E Mason; Olivier Elemento; C David Allis; Steven H Kleinstein; Ari M Melnick
Journal:  Cancer Cell       Date:  2020-05-11       Impact factor: 31.743

7.  Inhibition of herpes simplex virus gD and lymphotoxin-alpha binding to HveA by peptide antagonists.

Authors:  M R Sarrias; J C Whitbeck; I Rooney; L Spruce; B K Kay; R I Montgomery; P G Spear; C F Ware; R J Eisenberg; G H Cohen; J D Lambris
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

Review 8.  The role of lymphotoxin-α in rheumatoid arthritis.

Authors:  Tomohiro Hirose; Yuri Fukuma; Ayumu Takeshita; Keiichiro Nishida
Journal:  Inflamm Res       Date:  2018-03-14       Impact factor: 4.575

9.  Genome-wide DNA methylation patterns in naive CD4+ T cells from patients with primary Sjögren's syndrome.

Authors:  Nezam Altorok; Patrick Coit; Travis Hughes; Kristi A Koelsch; Donald U Stone; Astrid Rasmussen; Lida Radfar; R Hal Scofield; Kathy L Sivils; A Darise Farris; Amr H Sawalha
Journal:  Arthritis Rheumatol       Date:  2014-03       Impact factor: 10.995

10.  LTbetaR signaling induces cytokine expression and up-regulates lymphangiogenic factors in lymph node anlagen.

Authors:  Mark F Vondenhoff; Mascha Greuter; Gera Goverse; Dirk Elewaut; Pieter Dewint; Carl F Ware; Kerim Hoorweg; Georg Kraal; Reina E Mebius
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.